Literature DB >> 25826613

Short-term prognostic factors for primary sclerosing cholangitis.

Takeo Watanabe1,2, Kenji Hirano3,4, Minoru Tada3, Hiroyuki Isayama3, Suguru Mizuno3,5, Toshihiko Arizumi6, Nobuo Toda6, Yasuhiko Sugawara7, Norihiro Kokudo7, Kazuhiko Koike3.   

Abstract

BACKGROUND: It was recently reported that alkaline phosphatase (ALP) levels below 1.5 upper limit of normal (ULN) predicted better prognosis in primary sclerosing cholangitis (PSC). We evaluated whether ALP as well as other laboratory values were useful for the short-term prognosis of PSC in a Japanese cohort.
METHODS: In 78 patients with PSC (41 males and 37 females, mean onset age 41.9 years), the relationship between nine parameters (albumin, bilirubin, international normalized ratio of prothrombin time [PT-INR], ALP, aspartate aminotransferase [AST], alanine aminotransferase [ALT], γ-glutamyl transpeptidase [γ-GTP], platelet, and calculated Model for End-Stage Liver Disease [MELD] score), and liver related clinical endpoints (death due to liver failure, variceal bleeding, liver transplantation, and biliary carcinoma) were retrospectively examined. Using receiver operating characteristic (ROC) analysis, we investigated which parameter was useful for predicting the short-term prognosis.
RESULTS: Average follow-up period was 8.6 years. The endpoints were evaluated in 40 patients. Seven patients died of liver failure, three patients developed variceal bleeding, nine patients received liver transplantation from a living donor, 13 patients received certified brain-dead liver transplantation, and eight patients developed biliary carcinoma. The parameters with an area under the curve (AUC) of more than 0.8 were albumin, bilirubin, PT-INR, ALP, and MELD score. AUC for ALP was 0.85. The optimal cutoff value was 2.3 ULN. Despite the use or non-use of ursodeoxycholic acid, short-term prognosis of patients with an ALP level below 2.3 ULN was good.
CONCLUSIONS: We confirmed that keeping ALP low is associated with better short-term prognosis in a Japanese cohort. In addition, Alb, Bil, PT-INR, and MELD score were good predictors.
© 2015 Japanese Society of Hepato-Biliary-Pancreatic Surgery.

Entities:  

Keywords:  Alkaline phosphatase; MELD score; Primary sclerosing cholangitis; Prognosis; Ursodeoxycholic acid

Mesh:

Substances:

Year:  2015        PMID: 25826613     DOI: 10.1002/jhbp.238

Source DB:  PubMed          Journal:  J Hepatobiliary Pancreat Sci        ISSN: 1868-6974            Impact factor:   7.027


  5 in total

Review 1.  Primary Sclerosing Cholangitis: A Concise Review of Diagnosis and Management.

Authors:  Zachary P Fricker; David R Lichtenstein
Journal:  Dig Dis Sci       Date:  2019-02-06       Impact factor: 3.199

2.  Screening and surveillance for occupational cholangiocarcinoma in workers exposed to organic solvents.

Authors:  Shoji Kubo; Shigekazu Takemura; Shogo Tanaka; Takayoshi Nishioka; Masahiko Kinoshita; Genya Hamano; Tokuji Ito; Takatsugu Yamamoto; Makoto Abue; Masaru Aoki; Kei Nakagawa; Susumu Hijioka; Atsushi Miyamoto; Yukio Osaki; Ginji Endo; Shinji Kumagai
Journal:  Surg Today       Date:  2015-07-31       Impact factor: 2.549

3.  Gadoxetic acid-enhanced MRI in primary sclerosing cholangitis: added value in assessing liver function and monitoring disease progression.

Authors:  Aboelyazid Elkilany; Dominik Geisel; Tobias Müller; Andreas Fischer; Timm Denecke
Journal:  Abdom Radiol (NY)       Date:  2020-09-12

Review 4.  Risk stratification in autoimmune cholestatic liver diseases: Opportunities for clinicians and trialists.

Authors:  Palak J Trivedi; Christophe Corpechot; Albert Pares; Gideon M Hirschfield
Journal:  Hepatology       Date:  2015-11-26       Impact factor: 17.425

5.  Clinical guidelines for primary sclerosing cholangitis 2017.

Authors:  Hiroyuki Isayama; Susumu Tazuma; Norihiro Kokudo; Atsushi Tanaka; Toshio Tsuyuguchi; Takahiro Nakazawa; Kenji Notohara; Suguru Mizuno; Nobuhisa Akamatsu; Masahiro Serikawa; Itaru Naitoh; Yoshiki Hirooka; Toshifumi Wakai; Takao Itoi; Tomoki Ebata; Shinji Okaniwa; Terumi Kamisawa; Hiroki Kawashima; Atsushi Kanno; Keiichi Kubota; Masami Tabata; Michiaki Unno; Hajime Takikawa
Journal:  J Gastroenterol       Date:  2018-06-27       Impact factor: 7.527

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.